Welcome to our dedicated page for Evolus news (Ticker: EOLS), a resource for investors and traders seeking the latest updates and insights on Evolus stock.
Evolus Inc (EOLS) is a leading innovator in medical aesthetics, best known for Jeuveau, its FDA-approved botulinum toxin product for cosmetic lines. This page serves as the definitive source for verified Evolus news, providing investors and medical professionals with timely updates on corporate developments.
Access curated press releases and analysis covering regulatory milestones, financial results, and strategic partnerships. Our repository includes updates on aesthetic treatment innovations, market expansion efforts, and clinical research findings specific to Evolus' product pipeline.
Key coverage areas include quarterly earnings disclosures, manufacturing updates, physician adoption trends for Jeuveau, and international distribution agreements. All content is vetted for accuracy and relevance to stakeholders in the self-pay aesthetic sector.
Bookmark this page for efficient tracking of Evolus' performance in the competitive medical beauty market. Check regularly for objective reporting on operational developments and scientific advancements directly from corporate communications.
Evolus reported a 27% increase in sales for Q3 2022, reaching $33.9 million, primarily driven by a successful promotional campaign named ‘Switch Your Tox’. The campaign generated $3.5 million in incremental deferred revenue and reported a record of 100,000 consumer redemptions. Evolus maintains its 2022 revenue guidance of $143 to $150 million, projecting year-over-year growth of around 50%. The company's cash position stood at $65.6 million, expected to fund operations to breakeven, as operating expenses decreased to $51.8 million.
Evolus, Inc. (NASDAQ: EOLS), a company focused on beauty products, is participating in two investment conferences in November 2022. The first event is the Stifel 2022 Healthcare Conference on November 15, 2022, from 8:35-9:05 am ET. The second event is the 5th Annual Evercore ISI HealthCONx Conference on November 30, 2022, from 11:45-12:05 pm ET. Audio webcasts of both events will be available on Evolus’ investor relations website, with replays accessible for 90 days.
Evolus, Inc. (NASDAQ: EOLS) will release its third quarter 2022 financial results on November 8, 2022, after U.S. market close. A conference call will follow at 4:30 p.m. ET, allowing stakeholders to discuss the outcomes and participate in a Q&A session. Interested parties can join via phone at (877) 407-6184 for U.S. or (201) 389-0877 for international calls, or access the live webcast on the Evolus website. A replay will also be available post-call.
Evolus, Inc. (NASDAQ: EOLS) has initiated its commercial operations in Great Britain, marking a significant milestone in its global expansion strategy. The company has shipped its first orders for Nuceiva® (botulinum toxin type A), targeting the UK's largest aesthetic neurotoxins market. Evolus will also launch in Germany and Austria later in 2023 and aims for further European expansion. The company’s commitment to education for healthcare professionals is evident through its Innovator and Early Adopter programs, designed to enhance product understanding and application.
Evolus, Inc. (NASDAQ: EOLS) concluded certain royalty payments from a 2021 settlement with Medytox and Allergan, marking a significant milestone for the company's financial profile. CEO David Moatazedi reported expectations for improved profit margins and a robust growth outlook for 2022. The company anticipates an adjusted gross profit margin increase to 68%-71% for Q4 2022, up from 57.4% in Q2 2022. Additionally, Evolus plans to launch Nuceiva in Europe and is set to present preliminary data from a Phase II study in early 2023.
Evolus, Inc. (NASDAQ: EOLS) announced stock options and restricted stock units (RSUs) granted to Sandra Beaver, the new Chief Financial Officer, on September 5, 2022. These include 169,158 stock options with an exercise price of $9.06 and 36,443 RSUs. The options vest over four years, with 25% vesting annually. This grant complies with Nasdaq Listing Rule 5635(c)(4), emphasizing the company's commitment to attracting and retaining talent. Evolus focuses on innovative beauty products and the aesthetic neurotoxin market through its flagship product, Jeuveau®.
Evolus, Inc. has appointed Sandra Beaver as its new Chief Financial Officer, effective September 5, 2022. With over 20 years of financial expertise, Beaver previously served as Senior Vice President of Finance at Experian, overseeing significant revenue responsibilities. Her experience includes roles at International Game Technology where she led financial planning and analysis. President and CEO David Moatazedi highlighted her potential to enhance Evolus' growth and market share, particularly in the U.S. and Europe.
Evolus, Inc. (NASDAQ: EOLS), a leading performance beauty company, will participate in the H.C. Wainwright 24th Annual Global Investment Conference on September 12, 2022. The event will feature members of its management team, with an audio webcast available on demand starting at 7:00 am ET. Evolus focuses on innovative products tailored for beauty consumers, highlighting its flagship product, Jeuveau®, which is dedicated exclusively to aesthetics. More details are available on Evolus' website.
Evolus, Inc. (NASDAQ: EOLS) announced promising results from a peer-reviewed analysis showing that male patients treated with Jeuveau® achieved approximately 10% higher responder rates compared to those receiving BOTOX® in a Phase III trial. The analysis, involving 56 males, indicated a consistent trend favoring Jeuveau® despite not reaching statistical significance due to the small sample size. The increasing popularity of botulinum toxin treatments among men, which rose by 380% from 2000 to 2018, highlights the market potential for Jeuveau® in this demographic.
Evolus, Inc. (NASDAQ: EOLS) reported a 42% increase in Q2 2022 net revenue to $37.2 million, driven by higher volumes and a greater average selling price of Jeuveau®. The company anticipates achieving the upper end of its full-year 2022 guidance of $143 to $150 million, with projected year-over-year growth of nearly 50%. Evolus is set to launch Nuceiva® in Europe in Q3 2022 and maintains a strong cash position of $84.5 million. However, operating expenses rose to $58.5 million, resulting in a loss from operations of $21.3 million.
FAQ
What is the current stock price of Evolus (EOLS)?
What is the market cap of Evolus (EOLS)?
